A detailed history of Rhumbline Advisers transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Rhumbline Advisers holds 58,054 shares of PRCT stock, worth $4.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
58,054
Previous 61,872 6.17%
Holding current value
$4.71 Million
Previous $3.78 Million 23.05%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$56.31 - $84.99 $214,991 - $324,491
-3,818 Reduced 6.17%
58,054 $4.65 Million
Q2 2024

Aug 01, 2024

BUY
$45.73 - $69.19 $264,913 - $400,817
5,793 Added 10.33%
61,872 $3.78 Million
Q1 2024

May 09, 2024

BUY
$40.38 - $50.75 $62,225 - $78,205
1,541 Added 2.83%
56,079 $2.77 Million
Q4 2023

Feb 08, 2024

BUY
$24.89 - $43.41 $125,022 - $218,048
5,023 Added 10.14%
54,538 $2.29 Million
Q3 2023

Nov 09, 2023

BUY
$30.02 - $38.81 $59,169 - $76,494
1,971 Added 4.15%
49,515 $1.62 Million
Q2 2023

Aug 08, 2023

BUY
$26.7 - $37.02 $345,951 - $479,668
12,957 Added 37.46%
47,544 $1.68 Million
Q1 2023

May 11, 2023

BUY
$26.64 - $39.74 $21,178 - $31,593
795 Added 2.35%
34,587 $982,000
Q4 2022

Feb 14, 2023

BUY
$38.78 - $46.78 $50,724 - $61,188
1,308 Added 4.03%
33,792 $1.4 Million
Q3 2022

Nov 10, 2022

BUY
$30.9 - $50.65 $81,081 - $132,905
2,624 Added 8.79%
32,484 $1.35 Million
Q2 2022

Aug 11, 2022

BUY
$29.23 - $44.45 $661,591 - $1.01 Million
22,634 Added 313.23%
29,860 $976,000
Q1 2022

May 12, 2022

BUY
$16.89 - $35.74 $122,047 - $258,257
7,226 New
7,226 $253,000

Others Institutions Holding PRCT

About PROCEPT BioRobotics Corp


  • Ticker PRCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 44,592,300
  • Market Cap $3.62B
  • Description
  • PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...
More about PRCT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.